MyoKardia, Inc.
Overview
MyoKardia, Inc. is a biotechnology company focused on the development of targeted therapies for the treatment of serious cardiovascular diseases. It operates as a subsidiary of Bristol Myers Squibb, having been acquired in 2020. The company is renowned for its precision medicine approach to cardiac conditions.
Therapeutic areas
FDA compliance signals
No FDA recalls, Warning Letters, or Form 483 observations are linked to MyoKardia, Inc. in our records. PharmaTek screens the full directory against live FDA enforcement data.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.